Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Oncogene. 2020 Jun;39(26):4925-4943. doi: 10.1038/s41388-020-1341-1. Epub 2020 Jun 8.
Research about the role of gut microbiome in colorectal cancer (CRC) is a newly emerging field of study. Gut microbiota modulation, with the aim to reverse established microbial dysbiosis, is a novel strategy for prevention and treatment of CRC. Different strategies including probiotics, prebiotics, postbiotics, antibiotics, and fecal microbiota transplantation (FMT) have been employed. Although these strategies show promising results, mechanistically by correcting microbiota composition, modulating innate immune system, enhancing gut barrier function, preventing pathogen colonization and exerting selective cytotoxicity against tumor cells, it should be noted that they are accompanied by risks and controversies that can potentially introduce clinical complications. During bench-to-bedside translation, evaluation of risk-and-benefit ratio, as well as patient selection, should be carefully performed. In view of the individualized host response to gut microbiome intervention, developing personalized microbiome therapy may be the key to successful clinical treatment.
关于肠道微生物组在结直肠癌（CRC）中的作用的研究是一个新兴的研究领域。肠道微生物群调节旨在逆转已建立的微生物失调，是预防和治疗 CRC 的新策略。已经采用了不同的策略，包括益生菌、益生元、后生元、抗生素和粪便微生物群移植（FMT）。尽管这些策略显示出有前景的结果，但通过纠正微生物组成、调节先天免疫系统、增强肠道屏障功能、防止病原体定植和对肿瘤细胞发挥选择性细胞毒性，从机制上看，它们伴随着潜在的风险和争议，可能会带来临床并发症。在从实验室到临床的转化过程中，应仔细评估风险和收益比以及患者选择。鉴于宿主对肠道微生物组干预的个体化反应，开发个性化的微生物组疗法可能是成功临床治疗的关键。
